These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 28649953)

  • 1. Clinical restenosis and its predictors after implantation of everolimus-eluting bioresorbable vascular scaffolds: results from GABI-R.
    Mehilli J; Achenbach S; Woehrle J; Baquet M; Riemer T; Muenzel T; Nef H; Naber C; Richardt G; Zahn R; Gori T; Neumann T; Kastner J; Schmermund A; Hamm C
    EuroIntervention; 2017 Dec; 13(11):1319-1326. PubMed ID: 28649953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus-eluting bioresorbable scaffolds in patients with coronary artery disease: results from the German-Austrian ABSORB RegIstRy (GABI-R).
    Nef HM; Wiebe J; Kastner J; Mehilli J; Muenzel T; Naber C; Neumann T; Richardt G; Schmermund A; Woehrle J; Zahn R; Riemer T; Achenbach S; Hamm CW
    EuroIntervention; 2017 Dec; 13(11):1311-1318. PubMed ID: 28829745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical results of bioresorbable drug-eluting scaffolds in short and long coronary artery lesions using the PSP technique.
    Reichart C; Wöhrle J; Markovic S; Rottbauer W; Seeger J
    BMC Cardiovasc Disord; 2019 Jan; 19(1):22. PubMed ID: 30658574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study).
    Moscarella E; Tanaka A; Ielasi A; Cortese B; Coscarelli S; De Angelis MC; Piraino D; Latib A; Grigis G; Bianchi R; Buccheri D; Calabrò P; Tespili M; Silva Orrego P; Colombo A; Varricchio A
    Catheter Cardiovasc Interv; 2018 Oct; 92(4):668-677. PubMed ID: 29356269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical results of single and multiple bioresorbable drug-eluting scaffolds for treatment of de-novo coronary artery disease.
    Markovic S; Dragomir S; Walcher D; Bernhardt P; Imhof A; Rottbauer W; Wöhrle J
    Coron Artery Dis; 2016 Nov; 27(7):561-5. PubMed ID: 27244371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry.
    Geraci S; Kawamoto H; Caramanno G; Ruparelia N; Capodanno D; Brugaletta S; Gori T; Nef H; Sabate M; Mehilli J; Lesiak M; Naber C; Di Mario C; Capranzano P; Wiebe J; Araszkiewicz A; Pyxaras S; Mattesini A; Münzel T; Tamburino C; Colombo A; Latib A
    JACC Cardiovasc Interv; 2017 Mar; 10(6):560-568. PubMed ID: 28259663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
    Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
    JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials.
    Cassese S; Byrne RA; Jüni P; Wykrzykowska JJ; Puricel S; Ndrepepa G; Schunkert H; Fusaro M; Cook S; Kimura T; Henriques JPS; Serruys PW; Windecker S; Kastrati A
    EuroIntervention; 2018 Jan; 13(13):1565-1573. PubMed ID: 28671552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry.
    Felix CM; Fam JM; Diletti R; Ishibashi Y; Karanasos A; Everaert BR; van Mieghem NM; Daemen J; de Jaegere PP; Zijlstra F; Regar ES; Onuma Y; van Geuns RJ
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1652-63. PubMed ID: 27476094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procedural resources utilization and clinical outcomes with bioresorbable everolimus-eluting scaffolds and Pt-Cr everolimus-eluting stent with resorbable abluminal polymer in clinical practice. A randomized trial.
    de la Torre Hernandez JM; Garcia Camarero T; Lee DH; Sainz Laso F; Veiga Fernandez G; Pino T; Rubio S; Legarra P; Valdivia JR; Zueco Gil J
    Catheter Cardiovasc Interv; 2017 Aug; 90(2):E25-E30. PubMed ID: 27807948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorb Bioresorbable Scaffold Versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis: Rationale and Design of the COMPARE ABSORB Trial.
    Chang CC; Onuma Y; Achenbach S; Barbato E; Chevalier B; Cook S; Dudek D; Escaned J; Gori T; Kočka V; Tarantini G; West NEJ; Morice MC; Tijssen JGP; van Geuns RJ; Smits PC;
    Cardiovasc Revasc Med; 2019 Jul; 20(7):577-582. PubMed ID: 31153846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Results of the Absorb Diabetic Substudy.
    Kereiakes DJ; Ellis SG; Kimura T; Abizaid A; Zhao W; Veldhof S; Vu MT; Zhang Z; Onuma Y; Chevalier B; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2017 Jan; 10(1):42-49. PubMed ID: 28017311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
    Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent.
    Dalos D; Gangl C; Roth C; Krenn L; Scherzer S; Vertesich M; Lang I; Maurer G; Neunteufl T; Berger R; Delle-Karth G
    BMC Cardiovasc Disord; 2016 May; 16():104. PubMed ID: 27225486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanded clinical use of everolimus eluting bioresorbable vascular scaffolds for treatment of coronary artery disease.
    Diletti R; Ishibashi Y; Felix C; Onuma Y; Nakatani S; van Mieghem NM; Regar E; Valgimigli M; de Jaegere PP; van Ditzhuijzen N; Fam JM; Ligthart JMR; Lenzen MJ; Serruys PW; Zijlstra F; Jan van Geuns R
    Catheter Cardiovasc Interv; 2017 Jul; 90(1):58-69. PubMed ID: 27896897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective evaluation of a standardized strategy for the use of a polymeric everolimus-eluting bioresorbable scaffold in ST-segment elevation myocardial infarction: Rationale and design of the BVS STEMI STRATEGY-IT study.
    Ielasi A; Varricchio A; Campo G; Leoncini M; Cortese B; Vicinelli P; Brugaletta S; di Uccio FS; Latib A; Tespili M
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1129-1138. PubMed ID: 27774758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.
    Costopoulos C; Latib A; Naganuma T; Miyazaki T; Sato K; Figini F; Sticchi A; Carlino M; Chieffo A; Montorfano M; Colombo A
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):E10-5. PubMed ID: 24909303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of everolimus eluting bioabsorbable vascular scaffold (BVS) compared to non BVS drug eluting stent in the management of ST-segment elevation myocardial infarction (STEMI) - A comparative study.
    Chakraborty R; Patra S; Banerjee S; Pande A; Khan A; Mandol PC; Ghosh D; De SK; Das SS; Nag R
    Cardiovasc Revasc Med; 2016; 17(3):151-4. PubMed ID: 26905052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
    Muramatsu T; Onuma Y; van Geuns RJ; Chevalier B; Patel TM; Seth A; Diletti R; García-García HM; Dorange CC; Veldhof S; Cheong WF; Ozaki Y; Whitbourn R; Bartorelli A; Stone GW; Abizaid A; Serruys PW; ; ; ; ; ;
    JACC Cardiovasc Interv; 2014 May; 7(5):482-93. PubMed ID: 24746650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.